According to a new market research report “Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) – Global Forecast to 2022” published by MarketsandMarkets™, the market is expected to reach USD 4.19 Billion by 2022 from an estimated USD 3.63 Billion in 2017, at a CAGR of 2.9%.
Browse 53 Market Data Tables and 39 Figures spread through 236 Pages and in-depth TOC on “Overactive Bladder Treatment Market“
Early buyers will receive 10% customization on this report
The key factors driving the growth of this market include rising prevalence of overactive bladder, aggressive marketing strategies adopted by the players in this market, and the development of innovative therapies. However, the undesired systemic effects caused by the current oral therapies may hinder the growth of this market to a certain extent.
By pharmacotherapies, the anticholinergics segment accounted for the largest share of the market in 2016
On the basis of pharmacotherapies, the Overactive Bladder Treatment Market is broadly segmented into anticholinergics, mirabegron, BOTOX, and neurostimulation. Anticholinergics being the first line of medical treatment on OAB accounted for the largest share of this market in 2016. Among the anticholinergics class of drugs, solifenacin accounted for the largest share of this market owing to its efficacy as compared to the other drugs of the same class.
Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=219938791
By disease type, idiopathic bladder overactivity held the largest market share in 2016
Based on disease type of overactive bladder, the market is further categorized into idiopathic and neurogenic bladder overactivity. The neurogenic bladder overactivity segment is further categorized into Parkinson’s disease (PD), stroke, multiple sclerosis (MS), and spinal cord injury that lead to overactive bladder. In 2017, the idiopathic bladder overactivity segment is expected to account for the largest share of the bladder overactivity treatment market. The high share of this segment can be attributed to its high prevalence; women are more susceptible to the condition owing to bladder muscle weakness post pregnancy and menopause.
Speak to Analyst @ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=219938791
The U.S. dominated the market in 2016
The U.S. accounted for the largest share of the Overactive Bladder Treatment Market in 2016, followed by Europe and Asia-Pacific. Factors such as its well-established healthcare industry, favorable reimbursement policy, and demographics prone to bladder overactivity are contributing to the large share of the U.S. The rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness on the diseases due to the aggressive marketing campaigns adopted by pharma companies are majorly contributing to the growth of the European Overactive Bladder Treatment Market, which holds the second-largest market share.
The key players in the global Overactive Bladder Treatment Market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Allergan, Plc. (Ireland), Teva Pharmaceutical Industries Limited (Israel), Mylan N.V. (U.S.), Medtronic plc (Ireland), Endo International plc (Ireland), Sanofi (France), Hisamitsu Pharmaceutical Co., Inc. (Japan), Aurobindo Pharma Limited (India), Apotex Inc. (Canada), and Cogentix Medical, Inc. (U.S.)
